ADULT T-CELL LEUKEMIA/LYMPHOMA
Clinical trials for ADULT T-CELL LEUKEMIA/LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADULT T-CELL LEUKEMIA/LYMPHOMA trials appear
Sign up with your email to follow new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control rare blood cancer
Disease control CompletedThis phase 2 trial tested a combination of belinostat (a cancer drug) and zidovudine (AZT, an HIV drug) as consolidation therapy for adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. Fifteen participants received the drugs to see if it could eliminate can…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New combo shows promise against tough lymphoma
Disease control CompletedThis study tested a combination of brentuximab vedotin and standard chemotherapy (CHP) in 82 people newly diagnosed with a rare type of lymphoma called peripheral T-cell lymphoma (PTCL). The goal was to see how many patients had their tumors shrink or disappear after treatment. R…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Matched conditions: ADULT T-CELL LEUKEMIA/LYMPHOMA
Phase: PHASE2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC